Replies to post #447839 on Anavex Life Sciences Corp (AVXL)

[bas2020]

Unfortunately, he's not...

You are better than that.

[williamssc]

Phase 2b/3 12/01/22 press release still stands- ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,

SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE

The approved mab saw amyloid plaque reduction but also had SAE's brain bleeds even death. Blarcamesine reported to not only reduce amyloid plaques safely, patients also found to have a reduction in brain volume loss. Reduction in brain loss is a huge finding.

Reducing plaques is a marker but still the standard in the archaic FDA.
WGT